Published : Sep-2017
No. of Pages : 613
1 Table of Contents 2
1.1 List of Tables 13
1.2 List of Figures 20
2 Introduction 21
2.1 Injectable Drug Delivery Overview 21
3 Products under Development 22
3.1 Injectable Drug Delivery - Pipeline Products by Stage of Development 22
3.2 Injectable Drug Delivery - Pipeline Products by Segment 23
3.3 Injectable Drug Delivery - Pipeline Products by Territory 24
3.4 Injectable Drug Delivery - Pipeline Products by Regulatory Path 25
3.5 Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 26
3.6 Injectable Drug Delivery - Ongoing Clinical Trials 27
4 Injectable Drug Delivery - Pipeline Products under Development by Companies 28
4.1 Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 28
4.2 Injectable Drug Delivery - Pipeline Products by Stage of Development 32
5 Injectable Drug Delivery Companies and Product Overview 36
5.1 Aciont Inc Company Overview 36
5.2 Adamis Pharmaceuticals Corp Company Overview 38
5.3 AdrenaCard, Inc. Company Overview 40
5.4 Allergan Inc Company Overview 41
5.5 Alsensa ApS Company Overview 42
5.6 AMAG Pharmaceuticals Inc Company Overview 43
5.7 Antares Pharma Inc Company Overview 44
5.8 Anterion Therapeutics, Inc. (Inactive) Company Overview 48
5.9 Arnali, LLC Company Overview 50
5.10 Artemes Technologies, Inc. Company Overview 51
5.11 Ascendis Pharma A/S Company Overview 52
5.12 Ascil Proyectos SL Company Overview 55
5.13 AstraZeneca Plc Company Overview 56
5.14 Atanse, Inc. Company Overview 57
5.15 AzureBio SL Company Overview 59
5.16 Becton Dickinson and Co Company Overview 60
5.17 Bespak Europe Ltd Company Overview 62
5.18 BioCorRx Inc Company Overview 64
5.19 BioMarin Pharmaceutical Inc Company Overview 65
5.20 BioRestorative Therapies Inc Company Overview 66
5.21 Bioxis Pharmaceuticals Company Overview 67
5.22 Boston University Company Overview 68
5.23 BTG Plc Company Overview 69
5.24 Burke Pharmaceuticals LLC Company Overview 71
5.25 Callisyn Biomedical Inc Company Overview 72
5.26 Cambridge Consultants Ltd Company Overview 74
5.27 Camurus AB Company Overview 75
5.28 Case Western Reserve University Company Overview 78
5.29 Cincinnati Children's Hospital Medical Center Company Overview 79
5.30 Clearside BioMedical Inc Company Overview 80
5.31 Consort Medical plc Company Overview 84
5.32 CrossCoat Medical LLC Company Overview 86
5.33 DALI Medical Devices Ltd. Company Overview 87
5.34 Delcath Systems Inc Company Overview 91
5.35 DelSite, Inc. (Inactive) Company Overview 95
5.36 Elcam Medical Company Overview 96
5.37 EmboMedics Company Overview 100
5.38 Emergent BioSolutions Inc Company Overview 101
5.39 Eveon SAS Company Overview 102
5.40 Ferring Pharmaceuticals A/S Company Overview 104
5.41 Ghent University Company Overview 105
5.42 Hannover Medical School Company Overview 106
5.43 Inovio Pharmaceuticals Inc Company Overview 107
5.44 InVivo Therapeutics Corp Company Overview 109
5.45 kaleo Inc Company Overview 110
5.46 LyoGo Company Overview 111
5.47 Medicom Innovation Partner a/s Company Overview 112
5.48 Meridian Medical Technologies Inc Company Overview 113
5.49 Mertiva AB Company Overview 114
5.50 Micron Biomedical Inc Company Overview 115
5.51 Midatech Pharma Plc Company Overview 116
5.52 Milestone Scientific Inc Company Overview 117
5.53 North Carolina State University Company Overview 120
5.54 Ocelus Company Overview 121
5.55 Particle Therapeutics Ltd Company Overview 122
5.56 Pfizer Inc Company Overview 123
5.57 Portal Instruments Inc Company Overview 124
5.58 pSivida Corp Company Overview 125
5.59 QuiO Technologies LLC Company Overview 132
5.60 Radius Health Inc Company Overview 133
5.61 Ratio Inc Company Overview 134
5.62 Recon Therapeutics, LLC Company Overview 136
5.63 Replenish Inc Company Overview 137
5.64 RepliCel Life Sciences Inc Company Overview 138
5.65 Rescitech Vision Pvt Ltd Company Overview 139
5.66 RetinaPharma Technologies Inc Company Overview 140
5.67 Roche Diagnostics International Ltd Company Overview 141
5.68 Rx Safes Inc Company Overview 144
5.69 Scandinavian Health Ltd Company Overview 145
5.70 Sensile Medical AG Company Overview 146
5.71 SMC Ltd Company Overview 149
5.72 SpineSmith Holdings, LLC Company Overview 150
5.73 Sun Pharma Advanced Research Company Ltd Company Overview 151
5.74 TCB medical devices Company Overview 152
5.75 Teva Pharmaceutical Industries Ltd Company Overview 153
5.76 Texas Tech University Company Overview 155
5.77 TheraKine Inc (Inactive) Company Overview 156
5.78 Twin Star Medical Inc Company Overview 158
5.79 Unilife Corporation Company Overview 159
5.80 United Therapeutics Corp Company Overview 162
5.81 University College London Company Overview 163
5.82 University of Auckland Company Overview 164
5.83 University of Calgary Company Overview 165
5.84 University of California Irvine Company Overview 166
5.85 University of California San Diego Company Overview 167
5.86 University of California San Francisco Company Overview 169
5.87 University of Delaware Company Overview 170
5.88 University of Dundee Company Overview 171
5.89 University of Florida Company Overview 172
5.90 University of Missouri Company Overview 174
5.91 University of Saskatchewan Company Overview 175
5.92 University of Texas at Austin Company Overview 176
5.93 Vanderbilt University Company Overview 178
5.94 West Pharmaceutical Services Inc Company Overview 179
5.95 Windgap Medical Inc Company Overview 180
5.96 XERIS Pharmaceuticals Inc Company Overview 181
5.97 Ypsomed Holding AG Company Overview 182
6 Injectable Drug Delivery- Recent Developments 183
6.1 Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 183
6.2 Sep 01, 2017: Kaleo Donates Thousands of EVZIO (naloxone HCl injection) Auto-injectors to Hurricane Harvey Relief Efforts 184
6.3 Sep 01, 2017: Kaleo Donates Thousands of AUVI-Q (epinephrine injection, USP) Auto-injectors to Hurricane Harvey Relief Efforts 185
6.4 Aug 30, 2017: Repatha Receives Approval for New 420mg Single-Dose Delivery Option in Japan 186
6.5 Aug 29, 2017: Delcath Announces Medical University of Hannover in Germany Celebrates 100th CHEMOSAT Treatment 186
6.6 Aug 28, 2017: Catalent Reports Fourth Quarter and Full Year 2017 Results 187
6.7 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 189
6.8 Aug 21, 2017: Shire Director and Senior Management Changes 192
6.9 Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 193
6.10 Aug 18, 2017: District Court Issues Final Judgment - Retractable Technologies v. Becton, Dickinson 195
6.11 Aug 17, 2017: Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen Auto-Injector 195
6.12 Aug 17, 2017: Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability for Underpaying EpiPen Rebates 196
6.13 Aug 16, 2017: Astrazeneca Non-executive Director Retirement 197
6.14 Aug 15, 2017: Changes in Novo Nordisk Executive Management 197
6.15 Aug 14, 2017: Milestone Scientific Provides Business Update for the Second Quarter of 2017 198
6.16 Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 199
6.17 Aug 09, 2017: Clearside Biomedical Announces Second Quarter 2017 Financial Results and Provides Corporate Update 199
6.18 Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 201
6.19 Aug 08, 2017: Milestone Scientific Announces First Patient Treated with CompuFlo Epidural Instrument at University of Miami Hospital 206
6.20 Aug 08, 2017: Delcath Announces Second Quarter 2017 Financial Results 207
6.21 Aug 08, 2017: Clearside Biomedical Announces Changes to its Board of Directors 209
6.22 Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 209
6.23 Aug 08, 2017: Antares Pharma Reports Second Quarter 2017 Operating And Financial Results 211
6.24 Aug 07, 2017: Kaleo Announces AUVI-Q (epinephrine injection, USP) Charitable Donation Program for All Public Elementary Schools in the United States 212
6.25 Aug 03, 2017: Q2 2017: Merck Sets Course for Future Growth 214
6.26 Aug 03, 2017: Executive Board Changes at Merck 216
6.27 Aug 03, 2017: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 216
6.28 Aug 03, 2017: BD Announces Results For 2017 Third Fiscal Quarter 220
6.29 Aug 03, 2017: Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance 221
6.30 Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 225
6.31 Aug 02, 2017: BioMarin Announces Second Quarter 2017 Financial Results 227
6.32 Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 230
6.33 Aug 01, 2017: MRI Interventions Reports 79% Revenue Increase and Record Treatments in Second Quarter 2017 234
6.34 Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 237
6.35 Jul 31, 2017: Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences 244
6.36 Jul 31, 2017: Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense 244
6.37 Jul 27, 2017: U.S. FDA Grants Priority Review for an Epinephrine Auto-Injector in Development by Kaleo Specifically for Infants and Small Children 245
6.38 Jul 27, 2017: AstraZeneca Announce H1 2017 Results 246
6.39 Jul 27, 2017: Alkermes Reports Second Quarter 2017 Financial Results 253
6.40 Jul 27, 2017: Dr. Reddy's Q1 FY18 Financial Results 254
6.41 Jul 27, 2017: West Announces Second-Quarter 2017 Results 255
6.42 Jul 27, 2017: United Therapeutics Reports Second Quarter 2017 Financial Results 257
6.43 Jul 25, 2017: Vancouver's EVA Vein Care Now Offers New Varicose Vein Treatment 259
6.44 Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio 260
6.45 Jul 25, 2017: Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance 260
6.46 Jul 24, 2017: Alisha A. Alaimo Appointed SVP of Biogen's US Therapeutic Operations 263
6.47 Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 264
6.48 Jul 21, 2017: Dr. Reddy's Laboratories: Update On US FDA Audit at API Cuernavaca Plant 264
6.49 Jul 21, 2017: Merck Opens New Application Laboratory in Shanghai 264
6.50 Jul 18, 2017: Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences 265
6.51 Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 266
6.52 Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 266
6.53 Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 267
6.54 Jul 11, 2017: Portal Instruments Appoints Wendy Dwyer as Chief Business Officer 269
6.55 Jul 11, 2017: Milestone Scientific Appoints Daniel Goldberger as CEO to Lead Transition to a Commercially Focused Global Medical Device Company 269
6.56 Jul 11, 2017: MRI Interventions Announces Record Second Quarter ClearPoint System Procedures, And a 79% Year-Over-Year Revenue Increase 270
6.57 Jul 10, 2017: Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs 271
7 Appendix 608
7.1 Methodology 608
7.2 About GlobalData 611
7.3 Contact Us 611
7.4 Disclaimer 611
1.1 List of Tables
Table 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
Table 2: Injectable Drug Delivery - Pipeline Products by Segment 25
Table 3: Injectable Drug Delivery - Pipeline Products by Territory 26
Table 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
Table 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
Table 6: Injectable Drug Delivery - Ongoing Clinical Trials 29
Table 7: Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 30
Table 8: Injectable Drug Delivery - Pipeline Products by Stage of Development 34
Table 9: Aciont Inc Pipeline Products & Ongoing Clinical Trials Overview 38
Table 10: DSP - Visulex - Product Status 38
Table 11: DSP - Visulex - Product Description 38
Table 12: Visulex-I - Product Status 39
Table 13: Visulex-I - Product Description 39
Table 14: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 40
Table 15: Symjepi - Product Status 40
Table 16: Symjepi - Product Description 40
Table 17: Symjepi - Junior Version - Product Status 41
Table 18: Symjepi - Junior Version - Product Description 41
Table 19: AdrenaCard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
Table 20: Adrenacard Auto-Injector - Product Status 42
Table 21: Adrenacard Auto-Injector - Product Description 42
Table 22: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 43
Table 23: NOVADUR Intravitreal Implant - Product Status 43
Table 24: NOVADUR Intravitreal Implant - Product Description 43
Table 25: Alsensa ApS Pipeline Products & Ongoing Clinical Trials Overview 44
Table 26: SQJCT - Product Status 44
Table 27: SQJCT - Product Description 44
Table 28: AMAG Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 45
Table 29: Makena Auto-Injector - Product Status 45
Table 30: Makena Auto-Injector - Product Description 45
Table 31: Antares Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 46
Table 32: QuickShot Auto Injector - Product Status 46
Table 33: QuickShot Auto Injector - Product Description 47
Table 34: QuickShot Testosterone (QST) - Product Status 47
Table 35: QuickShot Testosterone (QST) - Product Description 47
Table 36: Teva Pen 1 - Product Status 48
Table 37: Teva Pen 1 - Product Description 48
Table 38: Vibex EPI - Product Status 48
Table 39: Vibex EPI - Product Description 48
Table 40: Vibex Qs - Makena - Product Status 49
Table 41: Vibex Qs - Makena - Product Description 49
Table 42: Vibex QS M - Product Status 49
Table 43: Vibex QS M - Product Description 49
Table 44: Anterion Therapeutics, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 50
Table 45: Ambulin - Product Status 50
Table 46: Ambulin - Product Description 50
Table 47: Choless - Product Status 51
Table 48: Choless - Product Description 51
Table 49: Complimens - Product Status 51
Table 50: Complimens - Product Description 51
Table 51: Arnali, LLC Pipeline Products & Ongoing Clinical Trials Overview 52
Table 52: Arnali Drug Delivery Device - Product Status 52
Table 53: Arnali Drug Delivery Device - Product Description 52
Table 54: Artemes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53
Table 55: Artemes Magnetic Injection System - Product Status 53
Table 56: Artemes Magnetic Injection System - Product Description 53
Table 57: Ascendis Pharma A/S Pipeline Products & Ongoing Clinical Trials Overview 54
Table 58: TransCon hGH Auto-Injector - Product Status 54
Table 59: TransCon hGH Auto-Injector - Product Description 54
Table 60: Ascendis Pharma A/S - Ongoing Clinical Trials Overview 55
Table 61: TransCon hGH Auto-Injector - Long-term Extension of HEIGHT Study 56
Table 62: Ascil Proyectos SL Pipeline Products & Ongoing Clinical Trials Overview 57
Table 63: Prefilled Device - Product Status 57
Table 64: Prefilled Device - Product Description 57
Table 65: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 58
Table 66: Second Generation Bydureon Pen - Product Status 58
Table 67: Second Generation Bydureon Pen - Product Description 58
Table 68: Atanse, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
Table 69: CEDSYS - Product Status 59
Table 70: CEDSYS - Product Description 59
Table 71: Intracerebral Microinjection Instrument - Product Status 60
Table 72: Intracerebral Microinjection Instrument - Product Description 60
Table 73: AzureBio SL Pipeline Products & Ongoing Clinical Trials Overview 61
Table 74: Injectable Needle - Product Status 61
Table 75: Injectable Needle - Product Description 61
Table 76: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 62
Table 77: BD Intevia Disposable Autoinjector - Product Status 62
Table 78: BD Intevia Disposable Autoinjector - Product Description 62
Table 79: BD Libertas Wearable Injector - Product Status 63
Table 80: BD Libertas Wearable Injector - Product Description 63
Table 81: T2 Patch Wearable Injector - Product Status 63
Table 82: T2 Patch Wearable Injector - Product Description 63
Table 83: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 64
Table 84: INJ650 ASI Auto-Injector - Product Status 64
Table 85: INJ650 ASI Auto-Injector - Product Description 64
Table 86: INJ700 Lila Mix Injector - Product Status 65
Table 87: INJ700 Lila Mix Injector - Product Description 65
Table 88: BioCorRx Inc Pipeline Products & Ongoing Clinical Trials Overview 66
Table 89: Naltrexone Implant - Product Status 66
Table 90: Naltrexone Implant - Product Description 66
Table 91: BioMarin Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
Table 92: Pegvaliase Pre-filled Syringe - Product Status 67
Table 93: Pegvaliase Pre-filled Syringe - Product Description 67
Table 94: BioRestorative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 68
Table 95: Curved Needle Device - Product Status 68
Table 96: Curved Needle Device - Product Description 68
Table 97: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 69
Table 98: Vaccine Delivery Device - Product Status 69
Table 99: Vaccine Delivery Device - Product Description 69
Table 100: Boston University Pipeline Products & Ongoing Clinical Trials Overview 70
Table 101: Polymeric Drug Delivery System - Product Status 70
Table 102: Polymeric Drug Delivery System - Product Description 70
Table 103: BTG Plc Pipeline Products & Ongoing Clinical Trials Overview 71
Table 104: Varithena - Product Status 71
Table 105: Varithena - Product Description 72
Table 106: Varithena - Aesthetic Leg Veins - Product Status 72
Table 107: Varithena - Aesthetic Leg Veins - Product Description 72
Table 108: Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 73
Table 109: BURKE201 Needle Injection Pen - Product Status 73
Table 110: BURKE201 Needle Injection Pen - Product Description 73
Table 111: Callisyn Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 74
Table 112: 8Spheres Embolic Microspheres - Product Status 74
Table 113: 8Spheres Embolic Microspheres - Product Description 74
Table 114: TACEspheres Drug Eluting Embolic Microspheres - Product Status 75
Table 115: TACEspheres Drug Eluting Embolic Microspheres - Product Description 75
Table 116: Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview 76
Table 117: Flexi-ject - Product Status 76
Table 118: Flexi-ject - Product Description 76
Table 119: Camurus AB Pipeline Products & Ongoing Clinical Trials Overview 77
Table 120: FluidCrystal Injection Depot - Setmelanotide - Product Status 77
Table 121: FluidCrystal Injection Depot - Setmelanotide - Product Description 77
Table 122: Camurus AB - Ongoing Clinical Trials Overview 78
Table 123: FluidCrystal Injection Depot - Setmelanotide - Phase Ia Study of Weekly Setmelanotide in Genetic Obesity 79
Table 124: Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview 80
Table 125: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Status 80
Table 126: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Description 80
Table 127: Cincinnati Children's Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 81
Table 128: Pre-Filled Syringe With Flush - Product Status 81
Table 129: Pre-Filled Syringe With Flush - Product Description 81
Table 130: Clearside BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview 82
Table 131: SCS Microinjector - Product Status 82
Table 132: SCS Microinjector - Product Description 82
Table 133: Clearside BioMedical Inc - Ongoing Clinical Trials Overview 83
Table 134: SCS Microinjector - A Phase III, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema Associated with Non-infectious Uveitis 84
Table 135: SCS Microinjector - A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Conjunction with Intravitreal Aflibercept in Subjects with Retinal Vein Occlusion: SAPPHIRE 84
Table 136: SCS Microinjector - Multi-center, Non-interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated with Non-infectious Uveitis 84
Table 137: SCS Microinjector - Phase I/II Study of CLS-1002 for Wet Age-related Macular Degeneration (AMD) 85
Table 138: Consort Medical plc Pipeline Products & Ongoing Clinical Trials Overview 86
Table 139: INJ200 Autoinjector - Product Status 86
Table 140: INJ200 Autoinjector - Product Description 86
Table 141: SYR075 - Product Status 87
Table 142: SYR075 - Product Description 87
Table 143: CrossCoat Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 88
Table 144: CCM-D - Product Status 88
Table 145: CCM-D - Product Description 88
Table 146: DALI Medical Devices Ltd. Pipeline Products & Ongoing Clinical Trials Overview 89
Table 147: SAN-DV - Product Status 89
Table 148: SAN-DV - Product Description 89
Table 149: SAN-DV Pro - Product Status 90
Table 150: SAN-DV Pro - Product Description 90
Table 151: SAN-L - Product Status 90
Table 152: SAN-L - Product Description 91
Table 153: SAN-Light Premium Safety Needle - Product Status 91
Table 154: SAN-Light Premium Safety Needle - Product Description 91
Table 155: SAN-P - Product Status 92
Table 156: SAN-P - Product Description 92
Table 157: Delcath Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 93
Table 158: Hepatic CHEMOSAT Delivery System - Product Status 93
Table 159: Hepatic CHEMOSAT Delivery System - Product Description 93
Table 160: Delcath Systems Inc - Ongoing Clinical Trials Overview 94
1.2 List of Figures
Figure 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
Figure 2: Injectable Drug Delivery - Pipeline Products by Segment 25
Figure 3: Injectable Drug Delivery - Pipeline Products by Territory 26
Figure 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
Figure 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
Figure 6: Injectable Drug Delivery - Ongoing Clinical Trials 29
